摘要
儿童间质性肺疾病(ChILD)是由多种少见慢性呼吸系统疾病组成、发生于儿童或者新生儿的一组疾病群。该病的发生、组成、诊疗过程及预后与成人间质性肺疾病都有一定的差异。近年对该病分子生物学层面研究发现其发病机制与组织异常修复、细胞反应产物以及细胞因子基因突变等有关,为揭示本病发生的分子学机制和治疗方案提供了有利的依据。由于临床发病较少,目前对其发病率尚无准确的统计,诊断及治疗标准亦未能明确界定,且总体治疗效果不够理想。现主要针对ChILD发病机制和治疗进展予以综述。
Children′s interstitial pneumonia（ChILD）is a combination of rare chronic respiratory diseases in children or newborns.The occurrence,composition,diagnosis,treatment,and prognosis differ from adult interstitial pneumonia.In recent years,with the progress of molecular biology study,it is found that abnormal tissue repair,cell reaction products,cytokines,and mutations are associated with the pathogenesis,respectively,revealing that the mechanism and treatment plan of this disease provide a favorable basis.Because the clinical onset is occult,its incidence is not currently available,the diagnosis and treatment standards are not clearly defined,and the overall treatment effect is not ideal.The article mainly reviews the pathogenesis and treatment for ChILD.
出处
《医学综述》
2011年第2期231-234,共4页
Medical Recapitulate
基金
南京军区福州总医院院内课题资助(200908)
关键词
儿童间质性肺疾病
肺泡损伤修复
治疗
Children′s interstitial lung disease
Alveolar damage-repair
Treatment
